Fig. 2From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspectiveTornado diagram: results of the one-way sensitivity analysisBack to article page